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Abstract 
Objectives: Surveillance intervals protocols after complete remission of intestinal 
metaplasia (CRIM) post radiofrequency ablation (RFA) in Barrett’s esophagus (BE) are 
currently empiric and not based on substantial evidence. We aimed to assess the 
timeline, location, and patterns of recurrence following CRIM to inform these guidelines.    
Design: Data on patients undergoing RFA for BE were obtained from prospectively 
maintained databases of five (three United States and 2 United Kingdom) tertiary referral 
centers. RFA was performed till CRIM was confirmed on two consecutive endoscopies.  
Results: 594 patients achieved CRIM as of May 1st 2017. 151 subjects developed 
recurrent BE over a median (IQR) follow up of 2.8 (1.4-4.4) years. There was 19% 
recurrence risk of any BE within 2 years and an additional 49% risk over the next 8.6 
years. The recurrence hazard rate of any BE, dysplastic BE, and high grade 
dysplasia/cancer remained constant over the duration of follow-up (p=0.74, p=0.94, and 
p=0.88; respectively). 74% of BE recurrences developed at the gastroesophageal 
junction (GEJ) (24.1% were dysplastic) and 26% in the tubular esophagus. The yield of 
esophageal random biopsies from the tubular esophagus, in the absence of visible 
lesions, was 1% (BE) and 0.2% (any dysplasia recurrence).   
Conclusions: BE recurrence risk following CRIM remained constant over time, 
suggesting that lengthening of follow up intervals, at least in the first five years after CRIM, 
may not be advisable. Sampling the GEJ is critical to detecting recurrence. The 
requirement for random biopsies of the neo-squamous epithelium in the absence of 
visible lesions may need to be re-evaluated.  
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What is already known about this subject? 
 Recurrence rates of intestinal metaplasia and dysplasia following successful 
ablation for Barrett’s esophagus are well established. 
 Recent data suggests that rates of recurrence are highest in the initial year after 
remission and may decline thereafter suggesting widening of surveillance intervals 
after the initial year. 
 Data on the timeline and endoscopic patterns of recurrence are scarce. 
What are the new findings? 
 Recurrence rates of intestinal metaplasia and dysplasia appear to increase 
progressively with time with no plateauing, in this multicenter international cohort 
study, 
 Yield of neo-squamous epithelium biopsies from the tubular esophagus in the 
absence of visible recurrences is very low (< 1.0%). 
 Most recurrences occur at the gastroesophageal junction (GOJ) or in the distal 5 
cm of the esophagus 
How might it impact on clinical practice in the foreseeable future?  
 Widening of surveillance intervals to detect recurrence after BE ablation may be 
premature in the absence of additional data. 
 Practice guidelines recommending Seattle protocol biopsies in the entire neo-
squamous epithelium in the absence of visible recurrences may need to be 
reevaluated.  
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Introduction 
Barrett’s esophagus (BE) is a condition that develops when the normal squamous 
epithelium is replaced by columnar mucosa with specialized intestinal metaplasia (IM). 
This process confers an increased risk of progression to esophageal adenocarcinoma 
(EAC) with an estimated incidence rate of approximately 0.33 per patient year.1 This risk 
increases significantly when either low grade dysplasia (LGD) or high grade dysplasia 
(HGD) develop in the setting of BE.2 Radiofrequency ablation (RFA) after endoscopic 
resection of visible lesions has been shown to significantly reduce the risk of cancer 
progression in patients with both LGD and HGD and has therefore become the standard 
of care in those patients.2 RFA is deemed to be successful once complete remission of 
intestinal metaplasia (CRIM) is achieved both endoscopically and histologically. However, 
recurrence of both IM and dysplasia occurs, with an estimated annual incidence rate of 
9.5% for any recurrence and 2% for dysplastic recurrences.3, 4 For these reasons, 
guidelines recommend regular surveillance every 3 months for the first year following 
CRIM, then every 6 months for the second year and then yearly afterwards.2  
Data from a recent systematic review suggest that recurrence rate may be significantly 
higher in the first year compared to subsequent years, raising the question, whether 
surveillance intervals should be extended to every 2 or 3 years instead of yearly after 
CRIM.5 However, this difference was not noted in the subgroup of studies defining CRIM 
more stringently as two negative endoscopies (n=3).6-8 The finding of columnar mucosa 
or IM on histology after one negative endoscopy may represent incompletely treated or 
missed prevalent disease rather than true recurrence and may therefore overestimate the 
recurrence rate.5 None of the latter studies evaluated the variation in the incidence of 
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recurrence over time across all grades of dysplasia. Moreover, other studies have thus 
far been limited by either small sample size (of CRIM patients with small number of 
dysplastic recurrences) 6, 9, 10 or the inclusion of large number of patients treated with no 
dysplasia whose recurrence patterns may not be reflective of those with dysplasia.11 
Hence, there is currently no conclusive evidence to demonstrate that the recurrence rate 
following CRIM remains constant over time (new cases developing every year) in order 
to justify currently recommended yearly surveillance or whether the rate plateaus after 
some time (no new cases developing) which may therefore justify widening surveillance 
intervals.  
Guidelines recommend that during surveillance after CRIM, random biopsies should be 
obtained from the gastroesophageal junction (GEJ) and the neo-squamous epithelium at 
1-2 cm intervals to cover the extent of the previous BE segment.2 Longitudinal data on 
the yield of this approach, particularly, in the absence of endoscopically visible recurrence 
are limited. Such data will be valuable in determining the cost effectiveness of this practice 
and in informing future guidelines. Similarly, the location of recurrence in the tubular 
esophagus needs to be better defined in order to justify surveillance biopsies over the 
entire length of the previous BE segment. 
Given these knowledge gaps, we aimed to assess the timeline, location, and patterns of 
recurrence following CRIM in a large multicenter, and international cohort with the goal of 
informing future guidelines for endoscopic surveillance after CRIM. We also used a 
conservative definition of CRIM as two consecutive negative endoscopies with biopsies 
(from the esophagus and GEJ) for the reasons detailed above.  
Materials and Methods 
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Study design 
This was a cohort study of patients undergoing RFA for BE in five tertiary referral centers 
with expertise in the management of this condition. Three centers were located in the 
United States (Mayo Clinic Rochester, Mayo Clinic Arizona, and Mayo Clinic Florida) and 
2 in the United Kingdom (Nottingham and Cambridge University Hospitals). The study 
was approved by the Institutional Review Boards of the respective centers. Data were 
obtained from prospectively maintained databases at each of the participating centers. 
We included patients who are 18 years or older with endoscopically (at least 1 cm of 
columnar mucosa in the tubular esophagus) and histologically (presence of IM) confirmed 
BE with or without dysplasia, who underwent RFA. Patients with advanced cancer stage 
(T2 or higher), pregnancy, or esophageal varices were excluded from the study. RFA 
procedures were performed between November 2003 and July 2016. All patients included 
in this study achieved CRIM between March 2004 and May 2017 and had at least one 
follow up endoscopy to check for recurrence. The study was conducted and reported 
according to the STROBE guidelines12. 
Participants and Interventions 
Patients underwent RFA by expert endoscopists following endoscopic assessment using 
high definition white light endoscopy and narrow band imaging with or without endoscopic 
resection of any visible lesions. Both circumferential and focal RFA was used to treat the 
BE segments as well as the GEJ. Energy settings followed manufacturer 
recommendations and RFA was performed every 3 months till CRIM was achieved. CRIM 
was defined as two consecutive endoscopies at least 3 months apart confirming the 
absence of IM on biopsies from both the GEJ (top of the gastric folds within 1 cm of the 
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neo-squamo-columnar junction) and tubular esophagus. In addition to RFA, patients 
could receive argon plasma coagulation or multipolar coagulation, as rescue (adjuvant) 
techniques for minimal residual BE islands.  
Post CRIM surveillance protocol 
Once CRIM was achieved, subsequent surveillance was performed at 3, 6, 9, and 12 
months thereafter. All patients underwent high definition white light endoscopy and 
narrow band imaging with random biopsy specimens obtained from the GEJ and every 1-
2 centimeters in 4 quadrants to cover the area of the previous BE segment as a minimum 
requirement. Samples from each level were labelled and stored in separate bottles. In 
addition, targeted biopsies were taken from any visible lesions (both columnar and/or neo-
squamous). Recurrence was defined as the histologic presence of IM with or without 
dysplasia on biopsy specimens taken from either the tubular esophagus or the GEJ or 
both after CRIM was achieved. The location, visibility, and the dysplasia status of all 
recurrences were documented. A separate sensitivity analysis was performed for 
recurrence incidence rate after excluding non-dysplastic BE (NDBE) recurrences at the 
GEJ given concern that this may represent residual IM or IM of the cardia rather than true 
BE recurrence.13 
Histology 
Baseline histology was recorded for all patients upon entry into the study and classified 
as: non-dysplastic BE (NDBE); indefinite for dysplasia (ID); LGD; HGD; and cancer. 
Biopsy specimens at each center were examined by an expert gastrointestinal 
pathologist. The worst grade of dysplasia detected on tissue sampling at baseline (pre-
RFA) and at post-CRIM surveillance (post-RFA) was assigned to that patient.    
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Statistical Analysis 
The Kaplan-Meier method was used to estimate the cumulative incidence of recurrence 
after CRIM. Tests of a constant recurrence hazard rate were performed with likelihood 
ratio tests comparing exponential vs. Weibull distributions for time to recurrence. Cox 
proportional hazards models were used to measure associations of a priori-set baseline 
variables with recurrence. Multivariable Cox models were used to estimate adjusted 
effects of each variable on recurrence, with Firth estimation in cases with low recurrence 
totals. A separate sensitivity analysis was performed for recurrence incidence rate after 
excluding NDBE recurrences at the GEJ given concern in some studies that this may 
represent residual IM or IM of the cardia rather than true BE recurrence.13    
Results 
Baseline Characteristics 
594 patients achieved CRIM as of May 1st 2017 and were included in the analysis (Table 
1). Figure 1 shows the patient flow chart. Mean (standard deviation (+/-SD)) age was 67 
(+/-10) years and 86% were males. Median (interquartile range (IQR)) BE segment length 
was 4 (2-6) cm. 90% of patients were treated for dysplasia or carcinoma.  
 
Table 1:   
Baseline characteristics of included patients (n=594). Data presented as  
number (%); mean (+/- standard deviation); or median (interquartile range).  
Variable Value 
Age, years 67 (+/-10) 
Male sex 509 (86%) 
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Body mass index 30.0 (+/-4.9) 
Length of Barrett's, cm (Prague M) 




Hiatal hernia presence 
- Length of hiatal hernia, cm 
492 (82.8%) 
3 (2-5) 
Pre-RFA baseline histology:  
- Non-dysplastic BE 
- Indefinite for dysplasia 
- Low grade dysplasia 








Pre-RFA endoscopic resection  
- Lesion histology: 
 Non-dysplastic BE 
 Indefinite for dysplasia 
 Low grade dysplasia 
 High grade dysplasia 
 Cancer 








78 (95.1%); 3 (3.7%), 1 (1.2%) 
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- Focal 287 (48.7%) 






BE, Barrett’s esophagus; RFA, radiofrequency ablation; CRIM, complete remission of 
intestinal metaplasia 
 
151 subjects developed recurrent BE (Table 2) over a median (IQR) follow up of 2.8 (1.4-
4.4) years.   
 
Table 2: Baseline characteristics of recurrent cases (n=151). Data presented as 
number (%). 
Recurrence parameter Value 
Location  
- Gastroesophageal junction: 
- Tubular esophagus: 
 
112 (74.2%) 
 39 (25.8%) 
Histology: overall, tubular esophagus, GEJ 
- Non-dysplastic BE 
- Indefinite for dysplasia 
- Low grade dysplasia 
- High grade dysplasia  
- Cancer 
 
104 (68.9%), 21 (13.9%), 83 (55%) 
3 (2.0%), 1 (0.7%), 2 (1.3%) 
18 (11.9%), 8(5.3%), 10 (6.6%) 
12 (7.9%), 4 (2.6%), 8 (5.3%) 
14 (9.3%), 5 (3.3%), 9 (6.0%) 
8 (5.3%), 2 (1.3%), 6 (4.0%) 
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 Stage T1a 
 Stage T1b 
 Stage T2 
4 (2.6%), 2 (1.3%), 2 (1.3%) 
2 (1.3%), 1 (0.65%), 1 (0.65%) 
Recurrence treated†  108 (71.5%) 
Recurrence treatment modality: 
- Endoscopic resection 
- Ablation 
- Endoscopic resection + ablation 
- Endoscopic resection + chemo-
radiation 
- Radiation only 
 
10 (9.3%) 




Recurrence treatment outcome 
- CRIM achieved 
- Ongoing endoscopic therapy 
- Lost to follow up 
- Esophagectomy +/- chemo-radiation 







†Recurrence not treated in 43 (28.5%) patients (n=27 awaiting treatment at the time of 
analysis; n=7 lost to follow up; n= 1 deceased/lung cancer; n=3 no intestinal metaplasia 
on follow up; n=5 surveillance only). GEJ, gastroesophageal junction; BE, Barrett’s 
esophagus; CRIM, complete remission of intestinal metaplasia.  
 
Recurrence incidence and timeline 
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The annual incidence rates of any recurrence, dysplastic recurrence, and HGD/cancer 
recurrence for the entire cohort are shown in Table 3.  
 
Table 3: Annual incidence rates of recurrent BE after complete remission of intestinal 






 HGD/cancer   
recurrence   
All recurrences in entire study cohort (n=594) 9.6% 2.8%  1.6% 
Excluding NDBE recurrence at GEJ (n=594) 4.3% 2.8%  1.6% 
Stratified by baseline histology pre-RFA    
- NDBE/ID subgroup (n=83) 5.2% 0.7%  0.7% 
- LGD subgroup (n=121) 5.9% 0.9%  0.9% 
- HGD/cancer subgroup (n=390) 12.4% 4.3%  2.3% 
HGD, high grade dysplasia; NDBE, non-dysplastic Barrett’s esophagus; GEJ, 
gastroesophageal junction; RFA, radiofrequency ablation; ID, indefinite for dysplasia; 
LGD, low grade dysplasia; HGD, high grade dysplasia.  
 
The recurrence hazard rate remained constant over the follow-up duration (p=0.74) with 
19% risk within 2 years and an additional 49% risk over the next 8.6 years. The recurrence 
hazard rate of dysplasia and HGD/Cancer while lower, also remained constant (p=0.94 
and p=0.88, respectively) over the duration of follow up (Figure 2). When NDBE 
recurrences at the GEJ were excluded, the recurrence hazard rate of any BE, dysplastic 
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BE, and HGD/cancer continued to remain constant over the follow up duration (p=0.94, 
0.88, and 0.94, respectively) (Supplementary Figure 1).  
Similarly, when stratified by baseline histology pre-RFA, the hazard rate of any recurrence 
remained constant over the follow-up duration in all the 3 groups of NDBE/ID (p=0.15), 
LGD (p=0.20), and HGD/cancer (p=0.91) (Figure 3). The hazard rate of dysplastic 
recurrence also remained constant in all the 3 groups of NDBE/ID (p=0.62), LGD 
(p=0.74), and HGD/cancer (p=0.87) (Figure 4). Recurrence rates were higher in those 
treated for HGD/cancer.  
 
Recurrence location 
BE recurred at the GEJ in 74.2% (n=112) of subjects and in the tubular esophagus in 
25.8% (n=39) (Table 2). 75.9% (n=85) of recurrences at the GEJ were non-dysplastic and 
all of those were non-visible and only detected on random biopsies from the GEJ. 24.1% 
(n=27) of recurrences at the GEJ were dysplastic. Of these, 59.3% (n=16) were visible 
endoscopically (Cancer n=9, HGD n=5, LGD n=2) and 40.7% (n=11) were non-visible 
(HGD n=3, LGD n=8) and only detected on random biopsies of the GEJ.  
 
82.1% (n=32) of recurrences in the tubular esophagus were visible endoscopically and 
84.4% of those were detected within 5 cm of the GEJ (Figure 5A). 17.9% (n=7) were non-
visible and only detected on random biopsies of the neo-squamous epithelium (Figure 
5B) (five were subsquamous and 2 had no mention of columnar mucosa on the 
endoscopy report, but histology showed IM with no squamous epithelium in the specimen 
bottle). Six out of these 7 patients had NDBE at 2 cm (n=3); 7 cm (n=2); and 9 cm (n=1) 
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from the GEJ. One patient had LGD at 4 cm from the GEJ. Therefore, the overall yield of 
random biopsy sampling for NDBE recurrence was only 1.0% (6/594) for any recurrence, 
and 0.2% (1/594) for dysplastic recurrence. 
Predictors of recurrence 
Baseline HGD/cancer but not LGD, predicted any recurrence (HR 1.95, 95%CI 1.07-3.56; 
p=0.029) (Supplementary Table 1) as well as dysplastic recurrence (HR 4.81, 95%CI 
1.21-19.18; p=0.026) (Supplementary Table 2). 
Supplementary Table 1:   
Multivariable model for any recurrence after complete remission of intestinal metaplasia  







 P value 
Age at CRIM 1.01 0.99-1.03  0.211 
Male sex  0.83 0.53-1.29  0.398 
Length of Barrett's cm (Prague M) 1.03 0.97-1.10  0.368 
Presence of hiatal hernia 1.62 0.93-2.82  0.087 
Baseline high grade dysplasia/cancer 1.95 1.07-3.56  0.029 
Baseline low grade dysplasia 1.01 0.52-1.97  0.971 
Endoscopic resection Pre-RFA 1.17 0.78-1.77  0.448 
Use of circumferential RFA device 1.17 0.75-1.83  0.495 








 P value 
Number of RFA sessions needed to 
CRIM 
1.07 0.93-1.23  0.344 
Use of other adjuvant ablation 
techniques 
1.22 0.87-1.72  0.242 
CRIM, complete remission of intestinal metaplasia; RFA, radiofrequency ablation. 
 
Supplementary Table 2:   
Multivariable model for dysplastic recurrence after complete remission of intestinal  







 P value 
Age at CRIM 1.02 0.98-1.05  0.381 
Male sex  1.77 0.58-5.39  0.317 
Length of Barrett's cm (Prague M) 1.08 0.97-1.21  0.165 
Presence of hiatal hernia 2.02 0.54-7.62  0.298 
Baseline high grade dysplasia/cancer 4.81 1.21-19.18  0.026 
Baseline low grade dysplasia 0.90 0.17-4.83  0.906 
Endoscopic resection Pre-RFA 0.76 0.38-1.51  0.433 
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Use of circumferential RFA device 1.58 0.65-3.82  0.313 
Number of RFA sessions needed to 
CRIM 
1.09 0.85-1.38  0.508 
Use of other adjuvant ablation 
techniques 
1.92 1.04-3.57  0.039 









In this large multicenter international cohort study, recurrence rates of NDBE, any 
dysplasia, and HGD/cancer following initial CRIM after RFA did not appear to plateau 
over the first 5-6 years of follow up, suggesting that continued yearly surveillance remains 
important, arguing against extending surveillance intervals at present, particularly in those 
with HGD/cancer at baseline. The majority of recurrences (74.2%) developed at the GEJ 
and approximately a quarter of those were dysplastic, of which a significant proportion 
(40.7%) were non-visible endoscopically. Most (84.4%) visible recurrences in the tubular 
esophagus were located within 5 cm of the GEJ. Finally, the yield of tubular esophageal 
biopsies in the absence of visible recurrence was very low for NDBE (1.0%) and 
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dysplastic BE (0.2%) which suggests that the requirement for random biopsies of the neo-
squamous epithelium in the absence of visible recurrence may need to be re-evaluated.  
 
A recent modelling study based on data from US and UK RFA registries suggested 
surveillance endoscopies at one and three years after CRIM for patients with baseline 
LGD and endoscopies at three months, six months, one year, and then annually 
thereafter for those with baseline HGD or cancer.11 The surveillance intervals were 
estimated only to a limit of five years to avoid extrapolation beyond available data. 
Therefore, there is a lack of clarity from current literature with regards to both the need 
for and the yield of surveillance beyond this time. Moreover, the latter model’s estimates 
were based on dysplastic recurrences only and did not account for the non-dysplastic 
(NDBE) ones. NDBE recurrences following CRIM may require therapy as those could 
represent an incompletely treated or missed prevalent disease and may still have 
neoplastic potential if left untreated.5 When NDBE recurrences at the GEJ were excluded 
(given concern that this may represent IM of the cardia rather than true BE recurrence13), 
the recurrence hazard rate across all grades of dysplasia remained constant over the 
duration of follow up (table 3 and supplementary figure 1). Our data suggests that 
continued surveillance beyond 5 years remains necessary. The recurrence rate in 
patients with LGD at baseline also remained constant over time, suggesting that long term 
surveillance is warranted in that group as well.   
The number of endoscopies required to define CRIM remains a subject of debate. 
Intestinal metaplasia is known to be patchy and may be missed on random biopsies.14 
Therefore, two endoscopies with biopsies may be required to confidently rule out the 
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presence of IM.14 To our knowledge, there are no data comparing 2 vs. more negative 
endoscopies on the recurrence rates on follow up and this may be an area for further 
research. None of the three studies that defined CRIM on 2 negative endoscopies 6-8 
evaluated the variation in the incidence of recurrence over time across all grades of 
dysplasia. In one single center study, 20% of patients had NDBE at baseline and no 
recurrences were reported after 3 years implying little benefit from surveillance beyond 3 
years post CRIM.6 This is in contrast to data from our study demonstrating that recurrence 
rate remained constant after 3 years.   
Previously, two smaller, single center studies reported that the majority of dysplastic 
recurrences developed in the gastric cardia and the majority of those were non-visible.10, 
15  Eighty percent of recurrences in the tubular esophagus were visible endoscopically 10 
and random biopsies >1 cm proximal to the GEJ had no yield for any recurrence.15 Data 
from the current study from a larger multicenter cohort showed that 82% of tubular 
esophageal recurrences were visible and the yield of random biopsies >1 cm proximal to 
the GEJ was extremely low (1.2% yield for any recurrence and 0.2% for dysplastic 
recurrence). The true rate of non-visible, sub-squamous recurrence remains hard to 
measure, but is likely to be rare based on current data.16 Volumetric laser 
endomicroscopy has been used to image post-RFA subsquamous glandular structures, 
but correlation with buried BE glands was poor in one study.17 More cost-effective and 
standardized imaging and sampling techniques are required in order to evaluate this 
outcome in a more systematic and precise manner. Moreover, data on the natural history 
of these recurrences are required.  
Study strengths and limitations 
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This study has several strengths. We evaluated a large sample of patients over a long 
follow up duration, which are important factors to achieve more precise estimates of the 
recurrence rates. Data were collected from multiple expert large volume centers located 
both in the UK and USA, which strengthens the validity and generalizability of our results. 
Furthermore, the vast majority of our patients (90%) received RFA for dysplastic BE which 
is representative of current clinical practice guidelines in contrast to several other studies 
of US populations where a large proportion of patients (up to 46%)11 have NDBE and 
therefore do not require RFA based on current evidence.2 Databases were prospectively 
maintained in all participating centers in order to minimize selection and recall biases. 
While centralized pathology was not utilized, all centers had dedicated expert 
gastrointestinal pathologists reading all BE histology.  
The study also has limitations. Biopsy sampling techniques and forceps size used were 
not standardized across centers and may therefore result in sampling error and case 
ascertainment bias. We attempted to minimize the latter by implementing a more 
conservative definition of CRIM with 2 negative endoscopies and biopsies for IM from 
both the GEJ and tubular esophagus. The multicenter nature of the study with different 
operators at centers of expertise, makes the study susceptible to variation in practices, 
but also helps to make our data more representative of real world practice. One caveat 
to the latter is that our study sample comes from tertiary referral centers, which may not 
be representative of results in community practice. However, the overwhelming number 
of these procedures are currently performed in settings similar to ours based on current 
society guidelines.2   
Conclusions and implications for clinical practice 
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This study demonstrates that the recurrence hazard rate of  recurrent NDBE, dysplastic 
BE, and HGD/cancer remained constant over time during surveillance in patients who 
achieved CRIM after RFA when strict criteria for the definition of CRIM are applied. This 
suggests that diligent long term (at least) yearly endoscopic surveillance remains 
important in these patients. The majority of all recurrences developed at the GEJ and a 
significant proportion of dysplastic recurrences were non-visible endoscopically. This re-
enforces the need for careful imaging and sampling of the GEJ despite the absence of 
any visible lesions. On the other hand, the majority of recurrences in the tubular 
esophagus are visible endoscopically and the yield of random biopsy sampling in the 
absence of visible lesions was very low in expert centers. These findings may need to be 
replicated in non-expert centers before further conclusions can be made with regards to 
the cost-effectiveness of this practice.  
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Figure 1: Patient flowchart. CRIM, complete remission of intestinal metaplasia. 
*Recurrence not treated in 43 patients (n=27 awaiting treatment at the time of analysis; 
n=7 lost to follow up; n= 1 deceased/lung cancer; n=3 no intestinal metaplasia on follow 
up; n=5 surveillance only). 
Figure 2: The timeline of recurrent Barrett’s esophagus (any recurrence; dysplastic 
recurrence; and high grade dysplasia (HGD)/cancer recurrence) following complete 
remission of intestinal metaplasia (CRIM). 
Figure 3: The timeline of any recurrence stratified by baseline histology prior to 
radiofrequency ablation. NDBE: non-dysplastic Barrett’s esophagus; LGD: low grade 
dysplasia; HGD: high grade dysplasia.  
Figure 4: The timeline of dysplastic recurrences stratified by baseline histology prior to 
radiofrequency ablation. NDBE: non-dysplastic Barrett’s esophagus; LGD: low grade 
dysplasia; HGD: high grade dysplasia. 
Figure 5: The location of visible (panel A) and non-visible (panel B) recurrences in the 
tubular esophagus (blue cylinder). Histology of non-visible recurrences is also shown in 
panel B (NDBE: non-dysplastic Barrett’s esophagus; LGD: low grade dysplasia). 
Supplementary Figure 1: The timeline of recurrent Barrett’s esophagus (any recurrence; 
dysplastic recurrence; and high grade dysplasia (HGD)/cancer recurrence) following 
complete remission of intestinal metaplasia (CRIM) and after excluding non-dysplastic 
recurrences at the gastroesophageal junction. 
 
